| sofosbuvir/velpatasvir / Generic mfg. |
| Recruiting | 4 | 100 | Canada, US | Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, Epclusa | Catherine Anne Chappell, Gilead Sciences | Hepatitis C, Chronic, Pregnancy; Infection | 12/24 | 12/25 | | |
| Active, not recruiting | 4 | 374 | US | Sofosbuvir/velpatasvir (Epclusa®) | Jennifer Havens, National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Gilead Sciences, University of Kentucky, Icahn School of Medicine at Mount Sinai, University of Bristol | Hepatitis C, Opioid-Related Disorders, Injection Drug Use | 08/24 | 12/24 | | |
IRCT20130812014333N1: Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19 |
|
|
| Recruiting | 3 | 80 | Kermanshah | sofosbuvir/velpatasvir - Generic mfg. | Gilead, Generic mfg., Kermanshah University of Medical Sciences | COVID-19 | | | | |
2018-003474-27: Multicenter trial for the treatment of acute Hepatitis C with Sofosbuvir/Velpatasvir |
|
|
| Not yet recruiting | 2 | 20 | Europe | Film-coated tablet, Epclusa® 400 mg/100 mg Filmtabletten | Hannover Medical School, Gilead Sciences, Inc., German Center for Infection Research (DZIF) | Adults with acute hepatitis C virus (HCV) infection, Adults with acute hepatitis C virus infection, Diseases [C] - Virus Diseases [C02] | | | | |
| Recruiting | 2 | 450 | US | Epclusa | University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | End Stage Renal Disease | 05/25 | 12/25 | | |
| Completed | 1/2 | 10 | US | Zepatier, Epclusa | University of Pennsylvania, Merck Sharp & Dohme LLC | Lung Diseases | 12/21 | 12/22 | | |
| Active, not recruiting | 1 | 26 | Canada | Sofosbuvir-velpatasvir (400 mg/100 mg), Epclusa, Ex Vivo Lung Perfusion (EVLP), Normothermic EVLP | University Health Network, Toronto, Gilead Sciences | Lung Transplant Infection, Hepatitis C | 01/20 | 12/24 | | |
NCT04382404: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir |
|
|
| Completed | 1 | 11 | US | Sofosbuvir-Velpatasvir Drug Combination, Epclusa | Catherine Anne Chappell, Gilead Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Hepatitis C, Chronic | 10/23 | 10/23 | | |
| Not yet recruiting | N/A | 1000 | NA | Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa], Epclusa | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Gilead Sciences | Hepatitis C in Substance Users | 08/23 | 05/24 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
